FILING ANALYSIS · THURSDAY, OCTOBER 29
NovoCure Ltd NVCR — 8-K: Results of Operations and Financial Condition
positive
NovoCure reported a 16% year-over-year increase in net revenues to $193 million, driven by 19% growth in active patients worldwide, and raised its 2026 guidance to $736-$743 million in net revenue and $24-$34 million in adjusted EBITDA
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →